Stock Research for HTBX

HTBX

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

HTBX Stock Chart & Research Data

The HTBX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the HTBX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


HTBX Due diligence Resources & Stock Charts

The HTBX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View HTBX Detailed Price Forecast - CNN Money CNN View HTBX Detailed Summary - Google Finance
Yahoo View HTBX Detailed Summary - Yahoo! Finance Zacks View HTBX Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View HTBX Trends & Analysis - Trade-Ideas Barrons View HTBX Major Holders - Barrons
NASDAQ View HTBX Call Transcripts - NASDAQ Seeking View HTBX Breaking News & Analysis - Seeking Alpha
Spotlight View HTBX Annual Report - CompanySpotlight.com OTC Report View HTBX OTC Short Report - OTCShortReport.com
TradeKing View HTBX Fundamentals - TradeKing Charts View HTBX SEC Filings - Bar Chart
WSJ View Historical Prices for HTBX - The WSJ Morningstar View Performance/Total Return for HTBX - Morningstar
MarketWatch View the Analyst Estimates for HTBX - MarketWatch CNBC View the Earnings History for HTBX - CNBC
StockMarketWatch View the HTBX Earnings - StockMarketWatch MacroAxis View HTBX Buy or Sell Recommendations - MacroAxis
Bullish View the HTBX Bullish Patterns - American Bulls Short Pains View HTBX Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View HTBX Stock Mentions - StockTwits PennyStocks View HTBX Stock Mentions - PennyStockTweets
Twitter View HTBX Stock Mentions - Twitter Invest Hub View HTBX Investment Forum News - Investor Hub
Yahoo View HTBX Stock Mentions - Yahoo! Message Board Seeking Alpha View HTBX Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for HTBX - SECform4.com Insider Cow View Insider Transactions for HTBX - Insider Cow
CNBC View HTBX Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for HTBX - OTC Markets
Yahoo View Insider Transactions for HTBX - Yahoo! Finance NASDAQ View Institutional Holdings for HTBX - NASDAQ


Stock Charts

FinViz View HTBX Stock Insight & Charts - FinViz.com StockCharts View HTBX Investment Charts - StockCharts.com
BarChart View HTBX Stock Overview & Charts - BarChart Trading View View HTBX User Generated Charts - Trading View




Latest Financial News for HTBX


UPDATE: Heat Biologics Doses First Patient in New Cohort of its Expanded Phase 2 Trial of HS-110 in Combination with Merck's KEYTRUDA(R) in Non-Small Cell Lung Cancer Trial
Posted on Monday January 14, 2019

DURHAM, NC / ACCESSWIRE / January 14, 2019 / Heat Biologics, Inc. (HTBX), a biopharmaceutical company developing therapies designed to activate a patient's immune system against cancer, today announced that it has dosed its first patient in its Phase 2 clinical trial investigating HS-110 in combination with Merck's anti-PD1 checkpoint inhibitor, KEYTRUDA® (pembrolizumab), in patients with advanced non-small cell lung cancer (NSCLC). This expansion of the Company's Phase 2 trial into first-line maintenance treatment with Keytruda follows positive interim results reported last year on previously treated patients receiving HS-110 in combination with Bristol-Myers Squibb's anti-PD-1 checkpoint inhibitor, Opdivo® (nivolumab).


Heat Biologics Doses First Patient in New Cohort of its Expanded Phase 2 Trial of HS-110 in Combination with Merck's KEYTRUDA(R) in Non-Small Cell Lung Cancer Trial
Posted on Monday January 14, 2019

DURHAM, NC / ACCESSWIRE / January 14, 2019 / Heat Biologics, Inc. (HTBX), a biopharmaceutical company developing therapies designed to activate a patient's immune system against cancer, today announced that it has dosed its first patient in its Phase 2 clinical trial investigating HS-110 in combination with Merck's anti-PD1 checkpoint inhibitor, KEYTRUDA® (pembrolizumab), in patients with advanced non-small cell lung cancer (NSCLC). This expansion of the Company's Phase 2 trial into first-line maintenance treatment with Keytruda follows positive interim results reported earlier this year on previously treated patients receiving HS-110 in combination with Bristol-Myers Squibb's anti-PD-1 checkpoint inhibitor, Opdivo® (nivolumab).


The Daily Biotech Pulse: Cancer Genetics Prices Offering, DiaMedica Delists From Canadian Exchange, Medigus CEO Quits
Posted on Thursday January 10, 2019

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks The following biotech stocks struck 52-week highs Jan. 9:  China SXT Pharmaceuticals Inc (NASDAQ: SXTC ...


Heat Biologics Provides Clinical and Business Update
Posted on Thursday January 10, 2019

DURHAM, NC / ACCESSWIRE / January 10, 2018 / Heat Biologics, Inc. (HTBX), a biopharmaceutical company developing therapies designed to activate a patient's immune system against cancer, today provided a business update regarding the company's progress and plans for 2019. Jeff Wolf, Heat's CEO, commented, "We have postponed reporting our most recent interim data to enable us to present this data at a leading oncology conference.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.